Shark nanobodies targeting fpv- vp2 protein and uses thereof

By developing shark-derived nanobodies targeting the FPV-VP2 protein, the problem of lack of effective treatment and diagnosis for feline panleukopenia virus (FPV) has been solved. High-affinity and highly stable VNAR antibodies are provided for neutralization and diagnosis, improving the therapeutic effect and diagnostic sensitivity of FPV infection.

CN120923617BActive Publication Date: 2026-07-24YANGTZE DELTA REGION INST OF TSINGHUA UNIV ZHEJIANG
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
YANGTZE DELTA REGION INST OF TSINGHUA UNIV ZHEJIANG
Filing Date
2025-08-28
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Currently, there are no effective shark-derived nanobodies targeting feline panleukopenia virus (FPV), traditional treatments lack targeting and neutralizing antibody development is difficult, and existing diagnostic reagents are insufficient.

Method used

Develop shark-derived nanobodies targeting the FPV-VP2 protein, including VNAR antibodies with specific CDR3 region amino acid sequences, for the preparation of neutralizing antibodies and diagnostic reagents. Use phage display technology to screen for high-affinity antibodies and carry out large-scale production via a prokaryotic expression system.

Benefits of technology

It provides high-affinity, high-stability, and easily modifiable VNAR antibodies for the neutralization and diagnosis of FPV infection, improving treatment efficacy and diagnostic sensitivity while reducing production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120923617B_ABST
    Figure CN120923617B_ABST
Patent Text Reader

Abstract

The application discloses a shark-derived nanobody targeting FPV-VP2 protein and application thereof. The amino acid sequence of the complementarity determining region 3 of the shark-derived nanobody is selected from the sequence shown in any one of SEQ ID NO. 16 to SEQ ID NO. 30, or a sequence homologous to the sequence shown in any one of SEQ ID NO. 16 to SEQ ID NO. 30; or the amino acid sequence of the shark-derived nanobody is selected from the sequence shown in any one of SEQ ID NO. 1 to SEQ ID NO. 15, or a sequence homologous to the sequence shown in any one of SEQ ID NO. 1 to SEQ ID NO. 15. The shark-derived VNAR nanobody has the advantages of small molecular weight, high affinity, high stability, easy genetic engineering, low production cost and the like.
Need to check novelty before this filing date? Find Prior Art